Abion
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Abion develops experimental cancer drugs and antiviral therapies, aiming to match treatments to individual patients based on their specific biological markers, a precision-medicine approach known as companion diagnostics.
Its drug candidates target conditions including non-small-cell lung cancer and a range of solid tumors, and are intended for use in clinical and hospital settings. Listed on KOSDAQ, Korea's tech-focused stock exchange, Abion's pipeline centers on biomarker-driven research to identify which patients are most likely to respond to a given therapy.
Summary is AI-generated and may contain errors · figures from DART filings
Abion in five facts
What does Abion do?
Abion develops experimental cancer drugs and antiviral therapies, aiming to match treatments to individual patients based on their specific biological markers, a precision-medicine approach known as companion diagnostics.
Where is Abion listed and in which sector?
Abion (Korean name: 에이비온) trades under KRX code 203400 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is Abion?
Its market capitalisation was US$46M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Abion's latest annual revenue and operating profit?
For fiscal year 2025, Abion reported revenue of US$664.3K, an operating loss of US$14.6M and a net loss of US$21.9M, per its annual report on DART (data retrieved from DART on 2026-09-29). Revenue was up 15.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-29
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on securities held by executives/major shareholdersOct 13
- Report on securities held by executives/major shareholdersOct 8
- Report on securities held by executives/major shareholdersOct 8
- Report on securities held by executives/major shareholdersOct 8
- Report on securities held by executives/major shareholdersOct 8
- DisclosureOct 7
- Trading suspension period changedOct 7
- Trading suspension period changedSep 30
- Other market noticeSep 30
- Material management matter relevant to investment decisionsSep 30
- DisclosureSep 11
- Trading suspension period changed (share consolidation/split registration)M&A · Sep 8
- Other market noticeSep 7
- Share-pledge agreement that may change the largest shareholder
Abion's largest shareholder (Telcon RF Pharmaceutical Co., Ltd.) pledged shares as loan collateral to a financial company, securing up to US$7.78M.
Ownership change · Jul 3 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Abion reported consolidated results for FY2025: revenue of US$609K (+15.8% year on year), an operating loss of US$13M and a net loss of US$19.7M.
Earnings · Feb 12